Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Swedish Orphan Biovitrum

388,60 SEK

-1,72 %

Mindre end 1K følgere

SOBI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-1,72 %
+15,31 %
+16,77 %
+13,96 %
+41,31 %
+23,13 %
+69,23 %
+188,23 %
+714,36 %

Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.

Læs mere
Markedsværdi
138,89 mia. SEK
Aktieomsætning
126,75 mio. SEK
Omsætning
28,24 mia.
EBIT %
3,07 %
P/E
279,57
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mia.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
28.4
2026

Delårsrapport Q1'26

6.5
2026

Generalforsamling '26

16.7
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse18.2.2026, 07.00

Swedish Orphan Biovitrum AB: Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030

Swedish Orphan Biovitrum
Selskabsmeddelelse5.2.2026, 07.00

Swedish Orphan Biovitrum AB: Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress

Swedish Orphan Biovitrum
Selskabsmeddelelse15.1.2026, 11.30

Swedish Orphan Biovitrum AB: Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook

Swedish Orphan Biovitrum

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse7.1.2026, 17.00

Swedish Orphan Biovitrum AB: Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data

Swedish Orphan Biovitrum
Selskabsmeddelelse13.12.2025, 16.00

Swedish Orphan Biovitrum AB: Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Swedish Orphan Biovitrum
Selskabsmeddelelse21.10.2025, 11.00

Swedish Orphan Biovitrum AB: Change in the Sobi Board of Directors

Swedish Orphan Biovitrum
Selskabsmeddelelse20.10.2025, 06.00

Swedish Orphan Biovitrum AB: Sobi Q3 2025 report: Accelerated growth and portfolio momentum

Swedish Orphan Biovitrum
Selskabsmeddelelse19.10.2025, 18.30

Swedish Orphan Biovitrum AB: Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report

Swedish Orphan Biovitrum
Selskabsmeddelelse30.9.2025, 06.00

Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi

Swedish Orphan Biovitrum
Selskabsmeddelelse29.8.2025, 06.00

Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi

Swedish Orphan Biovitrum
Selskabsmeddelelse21.8.2025, 10.35

Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares

Swedish Orphan Biovitrum
Selskabsmeddelelse16.7.2025, 06.00

Swedish Orphan Biovitrum AB: Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

Swedish Orphan Biovitrum
Selskabsmeddelelse15.7.2025, 17.15

Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

Swedish Orphan Biovitrum
Selskabsmeddelelse1.7.2025, 11.00

Swedish Orphan Biovitrum AB: Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Swedish Orphan Biovitrum
Selskabsmeddelelse27.6.2025, 22.55

Swedish Orphan Biovitrum AB: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease

Swedish Orphan Biovitrum
Selskabsmeddelelse8.5.2025, 09.30

Swedish Orphan Biovitrum AB: Bulletin from Sobi's Annual General Meeting (AGM)

Swedish Orphan Biovitrum
Selskabsmeddelelse29.4.2025, 06.00

Swedish Orphan Biovitrum AB: Sobi publishes Q1 2025 report: Portfolio continues to deliver

Swedish Orphan Biovitrum
Selskabsmeddelelse1.4.2025, 06.00

Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum
Selskabsmeddelelse31.3.2025, 09.00

Swedish Orphan Biovitrum AB: Sobi publishes Annual and sustainability report for 2024

Swedish Orphan Biovitrum
Selskabsmeddelelse5.2.2025, 07.00

Swedish Orphan Biovitrum AB: Sobi publishes Q4 2024 report: A solid ending to a strong year

Swedish Orphan Biovitrum
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.